Aethlon Medical reported fiscal first quarter results for the period ended June 30, 2026. The company raised approximately $4.0 million in gross proceeds through a public offering of common stock subsequent to the quarter-end. Cash and cash equivalents stood at approximately $4.9 million as of June 30, 2026. Operating expenses decreased 11.9% to approximately $1.6 million compared to $1.8 million in the prior-year period. Clinically, the company dosed the first participant in the third and final cohort of its Phase 1 oncology study in Australia and had a Long COVID manuscript accepted for publication. Aethlon Medical is a clinical-stage medical therapeutic company developing the Hemopurifier, an investigational extracorporeal immunotherapeutic platform designed to remove tumor-derived extracellular vesicles and enveloped viruses from circulation.
